Related Experiment Video
Updated: May 17, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
[Risk stratified thromboprophylaxis and management of thrombotic events in plasma cell neoplasms]
1Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Abstract:
Cancer-associated thrombosis is one of the most dangerous complications of plasma cell neoplasms. The occurrence of thrombotic events can disrupt treatment plans, compromise patients' quality of life, and even threaten their lives, which presents significant challenges in clinical management. Given the adverse impacts, the accurate identification of risk factors and the appropriate application of thromboprophylaxis are of great importance. This paper will discuss the epidemiology, risk assessment, and stratified thromboprophylaxis of thrombotic events in plasma cell neoplasms, with the aim of drawing clinicians' attention to this common complication and promoting the overall management of plasma cell tumor-related thrombotic diseases.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins

